HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Set Alert for Articles By Andrew McConaghie

Latest From Andrew McConaghie

Moderna Not Immune To COVID-19 Effects On Trials

Company suspends enrolment to trials as coronavirus travel restrictions bite.

Commercial Companies

Podcast: Biopharma's Moment To Deliver On Coronavirus And The People's Hope

Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.

UK Biotechs Seek Government Help As Economic ‘Heart Attack’ Threatens Sector

Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.

United Kingdom BioPharmaceutical

Big Pharma Leaders Show United Front On COVID-19

Costs will be an issue, but not today; industry and healthcare systems are working at breakneck speed to catch up with the deadly virus.

Coronavirus COVID-19 Companies

Coronavirus Update: Synairgen Tests First Inhaled Candidate, No New China Cases

More studies are being launched into possible treatments for patients hospitalised with COVID-19, with Roche launching a Phase III, placebo-controlled trial of Actemra.

Coronavirus COVID-19 Companies

Coronavirus Update: Fujifilm Drug Shows Promise, Arrowhead Halts Trial Screening, Novartis Unveils COVID-19 Measures

Flu drug produces encouraging results in Chinese trials, while Novartis CEO Vas Narasimhan shows his public health background with package of measures.

International Coronavirus COVID-19
See All
UsernamePublicRestriction

Register